Compare HNVR & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | PEPG |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.4M | 207.1M |
| IPO Year | 2022 | 2022 |
| Metric | HNVR | PEPG |
|---|---|---|
| Price | $26.43 | $2.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $24.50 | $11.17 |
| AVG Volume (30 Days) | 29.2K | ★ 639.6K |
| Earning Date | 04-27-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.49 | N/A |
| Revenue Next Year | $8.61 | N/A |
| P/E Ratio | $33.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $1.31 |
| 52 Week High | $27.94 | $7.80 |
| Indicator | HNVR | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 49.27 |
| Support Level | $26.41 | $1.60 |
| Resistance Level | $27.89 | $3.14 |
| Average True Range (ATR) | 0.70 | 0.18 |
| MACD | -0.13 | -0.06 |
| Stochastic Oscillator | 15.79 | 10.16 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.